🦠 🍄 🫁
Our Review on influenza- and COVID-19-associated pulmonary aspergillosis is out now in @LancetRespirMed !
Thread below! 🧵
Link to Lancet (free log-in required): https://t.co/f3bgKCcdlx
Free link (no log-in required): https://t.co/nBB0u7DMXw
Proud to see our review on viral reactivations and fungal infections in non-resolving lung injury featured as Paper of the Day by CCR!
@lenn_maessen@JannesHeylen@Acute_Pulmo_Med
Today's Paper of the Day is:
Viral reactivations and fungal infections in nonresolving ARDS
https://t.co/JKgcYjlUQ5
Join us to read 1 paper per day and stay up-to-date as we cover the spectrum of critical care across 2025
Kickoff meeting for the
🌌Galectin-3 targeted antifungal prophylaxis in ICU influenza (GALActIC)🌌
https://t.co/GS97plO8Yz project at @UZLeuven
Incredibly productive meeting with the Galactic team @carvalho_ago@s_feys@eurconfmedmycol@MSG_ERC
Looking back with extreme gratitude on the past four years, having defended my PhD thesis on virus-associated aspergillosis last Tuesday. I got to work with fantastic people (many of whom have become friends), both within and outside the fungal research community (1/4)
And lastly thanks to my colleagues, friends, family and most of all to my wife Liedewij and my son Briek, for everything they’ve done and for making life beautiful (4/4)
Wonderful to see this important research on interferon gamma in influenza-associated aspergillosis published by my fantastic colleague and friend @SeldeslachtsL !
🌟 Thrilled to announce the publication of our paper in #eBioMedicine#TheLancet! 🌟
Damping excessive viral-induced IFN-γ restores the impaired anti-Aspergillus immune response in influenza-associated pulmonary aspergillosis (IAPA). 🧫🦠
https://t.co/krEIziWxE4
📰New Review: Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients
Severe viral pneumonia affects several layers of the antifungal host response
Read more free here: https://t.co/f0CbItezFd
@s_feys
Pulmonary HSV & CMV in #COVID19#ARDS
🦠HSV reactivations common; ⬆️ alveolar inflammation post reactivation: may hinder resolution of inflammation/injury? Alveolar sampling appropriate if non-resolving ARDS. Antivirals could enhance outcome
🦠CMV rare
🖇️ https://t.co/Ht2Nxh1CbJ